<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="30045">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01830517</url>
  </required_header>
  <id_info>
    <org_study_id>HM-AMO-401</org_study_id>
    <nct_id>NCT01830517</nct_id>
  </id_info>
  <brief_title>Diurnal Variation in Hypertensive Stroke Patients</brief_title>
  <official_title>Comparison of the Effects of Amlodipine and Losartan on Blood Pressure and Diurnal Variation in Hypertensive Stroke Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hanmi Pharmaceutical Company Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hanmi Pharmaceutical Company Limited</source>
  <oversight_info>
    <authority>Korea: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study was conducted to evaluate and compare the effectiveness of Amodipin® (amlodipine
      camsylate) with that of Cozaar® (losartan potassium) in hypertensive patients with an acute
      ischemic stroke by measuring their 24-hour ambulatory BP (ABP).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2007</start_date>
  <completion_date type="Actual">February 2012</completion_date>
  <primary_completion_date type="Actual">June 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>24-hour ambulatory mean SBP</measure>
    <time_frame>baseline and 8weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>24H mean DBP, 24H mean SBP/DBP Variability,clinic SBP/DBP, awake, sleep, morning, evening, and prewake BPs, the morning surge, and the nocturnal dipping</measure>
    <time_frame>baseline and 8weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">84</enrollment>
  <condition>Hypertension</condition>
  <condition>Stroke</condition>
  <arm_group>
    <arm_group_label>amlodipine camsylate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>amlodipine camsylate 5mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>losartan potassium</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>losartan potassium 50mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amlodipine, Losartan</intervention_name>
    <arm_group_label>amlodipine camsylate</arm_group_label>
    <arm_group_label>losartan potassium</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. aged 35 to 85 years

          2. hypertensive patients who had an ischemic stroke

        Exclusion Criteria:

          1. patients aged below 35 years or above 86 years;

          2. patients who had a hemorrhagic stroke;

          3. patients whose systolic BP (SBP) was over 220 mmHg or whose diastolic BP (DBP) was
             above 120 mmHg during an acute phase, or whose SBP was over 180 mmHg or whose DBP was
             over 110 mmHg one week after their hospital visit;

          4. patients with secondary hypertension related to renovascular, endocrinologic, or
             pregnant conditions

          5. patients who went to bed in the middle of the day or very late at night; (6) patients
             who were using intravenous antico-agulants or thrombolytics;

        (7) patients with a severe stroke (NIH stroke scale &gt; 20); (8) patients who could not give
        their consent to investigators; (9) patients with severely impaired liver function (AST or
        ALT ≥ 100); (10) patients with severely impaired renal function (serum creatinine  ≥ 2.0
        mg/dL); (11) patients with cancer; (12) patients who were pregnant or lactating; (13)
        patients with other grave diseases such as hypertensive encephalopathy, aortic dissection,
        acute myocardial infarction, or severe congestive heart failure; and (14) patients who
        were allergic to the test or control drugs
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hyunwoo Nam, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>SMG-SNU Boramae Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Boramae Medical Center</name>
      <address>
        <city>Boramae-ro 5-gil 20, Dongjak-gu</city>
        <state>Seoul</state>
        <zip>156-707</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>April 2013</verification_date>
  <lastchanged_date>April 11, 2013</lastchanged_date>
  <firstreceived_date>April 10, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Cerebral Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Amlodipine</mesh_term>
    <mesh_term>Losartan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
